Inspire Trust Co. N.A. Buys 4,292 Shares of Pfizer Inc. (NYSE:PFE)

Inspire Trust Co. N.A. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 105,000 shares of the biopharmaceutical company’s stock after buying an additional 4,292 shares during the quarter. Inspire Trust Co. N.A.’s holdings in Pfizer were worth $2,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth about $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. acquired a new position in Pfizer in the 1st quarter worth about $28,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter valued at approximately $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Finally, Redburn Atlantic dropped their price objective on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Performance

Shares of PFE opened at $25.14 on Thursday. The company’s 50 day simple moving average is $24.52 and its 200-day simple moving average is $24.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market cap of $142.93 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.